biostudies-literatureBuechel MClovisTesaroCarisTakedaJ &amp; JPfizerOncoMedAbbVieMerckNovartisRochePTC TherapeuticsJanssenNCI NIH HHSAstraZenecaLillyEsperanceRoche/Genentech721-732https://www.ebi.ac.uk/biostudies/studies/S-EPMC8887593biostudies-literatureUnknown30(5)<h4>Background</h4>Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options.<h4>Design</h4>Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed.<h4>Results</h4>Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with Annals of oncology : official journal of the European Society for Medical OncologyTreatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.PMC8887593P50 CA217685Monk BJWestin SNBuechel MColeman RLHerzog TJMoore KNfalseTreatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.<h4>Background</h4>Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options.<h4>Design</h4>Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed.<h4>Results</h4>Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with 2019-01-01T00:00:00Z2019 May2025-04-18T12:09:44.086Z2025-04-06T21:48:58.377ZS-EPMC88875933088702010.1093/annonc/mdz104